Novartis AG to Discuss Kesimpta® FDA Approval Investor Call Transcript - Thomson StreetEvents

Novartis AG to Discuss Kesimpta® FDA Approval Investor Call Transcript

Novartis AG to Discuss Kesimpta® FDA Approval Investor Call Transcript - Thomson StreetEvents
Novartis AG to Discuss Kesimpta® FDA Approval Investor Call Transcript
Published Aug 21, 2020
Published Aug 21, 2020
Price US$ 54.00  |  Buy this Report Now

About This Report

  
Abstract:

Edited Transcript of NOVN.S conference call or presentation 21-Aug-20 2:30pm GMT

  
Report Type:

Transcript

Source:
Thomson StreetEvents
Company:
Novartis AG
Ticker
NOVN.S
Time
2:30pm GMT
Format:
PDF Adobe Acrobat
Buy Now

Novartis AG at Novartis Co-Creating Impact Summit (Virtual) - AM Session Transcript – 2020-12-09 – US$ 54.00 – Edited Transcript of NOVN.S presentation 9-Dec-20 7:00am GMT

Novartis AG, ABN Amro Bank NV & BlackRock Inc at Novartis Co-Creating Impact Summit (Virtual) - PM Session Transcript – 2020-12-09 – US$ 54.00 – Edited Transcript of NOVN.S presentation 9-Dec-20 12:00pm GMT

Virtual Meet Novartis AG Management Investor Event Transcript – 2020-11-24 – US$ 54.00 – Edited Transcript of NOVN.S corporate analyst meeting</ 24-Nov-20 1:00pm GMT

Novartis AG Q3 2020 Earnings Call Transcript – 2020-10-27 – US$ 54.00 – Edited Transcript of NOVN.S earnings conference call or presentation 27-Oct-20 1:00pm GMT

Novartis AG ESG Investor Event Transcript – 2020-09-01 – US$ 54.00 – Edited Transcript of NOVN.S corporate analyst meeting</ 1-Sep-20 12:00pm GMT

Novartis AG Q2 2020 Earnings Call Transcript – 2020-07-21 – US$ 54.00 – Edited Transcript of NOVN.S earnings conference call or presentation 21-Jul-20 12:00pm GMT

Novartis AG to Discuss the Oncology Pipeline Update Call Transcript – 2020-06-15 – US$ 54.00 – Edited Transcript of NOVN.S conference call or presentation 15-Jun-20 1:00pm GMT

Novartis AG Q2 2019 Earnings Call Summary – 2019-07-18 – US$ 54.00 – Edited Brief of NOVN.S earnings conference call or presentation 18-Jul-19 12:00pm GMT

Novartis AG Q2 2019 Earnings Call Transcript – 2019-07-18 – US$ 54.00 – Edited Transcript of NOVN.S earnings conference call or presentation 18-Jul-19 12:00pm GMT

Novartis AG to Discuss the Zolgensma® and Piqray® US FDA Approvals Call Summary – 2019-05-27 – US$ 54.00 – Edited Brief of NOVN.S conference call or presentation 27-May-19 2:30pm GMT

More from Thomson StreetEvents

Thomson StreetEvents—Thomson StreetEvents is a leading provider of Web-based solutions for the investment community, offering services that transform the way companies communicate and meet disclosure requirements while assisting investors in managing and leveraging this information. Thomson StreetEvents service offers institutional investors a one-stop solution for managing corporate disclosure information by aggregating conference calls, webcasts, transcripts, call summaries, and other financial information into a time-saving, efficiency tool.
Purchase Thomson StreetEvents' Transcripts (verbatim reports) and Briefs (call summaries) of earnings, guidance, M&A and other corporate calls directly through Alacra. Discounted prices apply to reports produced over two weeks ago.

About the Author


Cite this Report

  
MLA:
Thomson StreetEvents. "Novartis AG to Discuss Kesimpta® FDA Approval Investor Call Transcript" Aug 21, 2020. Alacra Store. May 11, 2025. <http://www.alacrastore.com/thomson-streetevents-transcripts/Novartis-AG-to-Discuss-Kesimpta-FDA-Approval-Investor-Call-T13362597>
  
APA:
Thomson StreetEvents. (2020). Novartis AG to Discuss Kesimpta® FDA Approval Investor Call Transcript Aug 21, 2020. New York, NY: Alacra Store. Retrieved May 11, 2025 from <http://www.alacrastore.com/thomson-streetevents-transcripts/Novartis-AG-to-Discuss-Kesimpta-FDA-Approval-Investor-Call-T13362597>
  
US$ 54.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Credit Research from one place.